Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
State-of-the-Art Drug Delivery in Europe
share announcement

State-of-the-Art Drug Delivery in Europe

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 5918

Special Issue Editors

Dr. Anca-Maria Arseniu

E-Mail Website
Guest Editor
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 2A Lucian Blaga St., 550169 Sibiu, Romania
Interests: drug delivery; drug design and synthesis; structural characterization; biological activity evaluation; structure-activity relationship; medicinal chemistry; pharmacovigilance
Special Issues, Collections and Topics in MDPI journals
Dr. Adriana Aurelia Chiș

E-Mail Website
Guest Editor
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 2A Lucian Blaga St., 550169 Sibiu, Romania
Interests: drug delivery strategies; nanoparticles; dendrimers conjugated with bioactive compounds; polymers conjugated with bioactive compounds; chronic diseases therapy; diagnosis; pharmacovigilance
Special Issues, Collections and Topics in MDPI journals
Dr. Luca-Liviu Rus

E-Mail Website
Guest Editor
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 2A Lucian Blaga St., 550169 Sibiu, Romania
Interests: analytical method development; analytical method validation; NIR Spectroscopy; chemometrics; quality control of health products; drug delivery; cosmetics
Special Issues, Collections and Topics in MDPI journals
Dr. Claudiu Morgovan

E-Mail Website
Guest Editor
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 2A Lucian Blaga St., 550169 Sibiu, Romania
Interests: safety and effectiveness of health products; pharmacotherapy; pharmacovigilance; nutrivigilance
Special Issues, Collections and Topics in MDPI journals
Dr. Jean A. Boutin

E-Mail Website
Co-Guest Editor
Institut de Recherches Internationales Servier, Suresnes, France
Interests: melatonin; enzymes; receptors; myristoylation; peptide; pseudopeptides; drug discovery; VHH
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nowadays, modern strategies in healthcare involve the development of drug delivery systems for targeted therapy and controlled drug release to improve clinical outcomes. The safety and effectiveness of many innovative delivery systems containing synthetic active substances or natural compounds, especially macromolecules, are being investigated. These innovative systems are developed based on a wealth of knowledge in the fields of pharmaceutical, medicine and engineering.

For this Special Issue, the authors are invited to present a wide range of topics on drug delivery including recent advances in the design and fabrication of health products, natural product-based delivery systems, and characterization of their efficiency and safety profile based on in vitro or in vivo studies.

For this Special Issue, we are soliciting the submission of original articles or review articles from researchers based in Europe, where the main focus of the article is research carried out in the field of drug delivery.

Best regards,

Dr. Anca-Maria Arseniu
Dr. Adriana Aurelia Chiș
Dr. Luca-Liviu Rus
Dr. Claudiu Morgovan
Dr. Jean A. Boutin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • treatment
  • chronic disease
  • cancer therapy
  • nanoparticles
  • dendrimers
  • polymers
  • macromolecules
  • bioactive compounds
  • pharmaceutical formulations
  • efficiency and safety profile

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 2808 KiB  
Article
Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance
by Claudiu Morgovan, Carmen Maximiliana Dobrea, Anca Butuca, Anca Maria Arseniu, Adina Frum, Luca Liviu Rus, Adriana Aurelia Chis, Anca Maria Juncan, Felicia Gabriela Gligor, Cecilia Georgescu, Steliana Ghibu and Andreea Loredana Vonica-Tincu
Biomedicines 2024, 12(5), 953; https://doi.org/10.3390/biomedicines12050953 - 25 Apr 2024
Viewed by 330
Abstract
Trastuzumab (T) and tyrosine kinase inhibitors (TKIs) are among the first-line treatments recommended for HER2-positive breast cancer. More recently, antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have been authorized, and they represent the second-line therapy in this type [...] Read more.
Trastuzumab (T) and tyrosine kinase inhibitors (TKIs) are among the first-line treatments recommended for HER2-positive breast cancer. More recently, antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have been authorized, and they represent the second-line therapy in this type of cancer. The present study aimed to evaluate adverse drug reactions (ADRs) associated with T-based ADCs that were spontaneously reported in EudraVigilance—the European pharmacovigilance database. Out of 42,272 ADRs reported for currently approved ADCs on the market, 24% of ADRs were related to T-DM1, while 12% of ADRs were related to T-DXd. T-DM1 had a higher probability of reporting eye, ear and labyrinth, and cardiac and hepatobiliary ADRs, while T-DXd had a higher probability of reporting respiratory, thoracic and mediastinal, blood and lymphatic system, metabolism and nutrition, and gastrointestinal ADRs. The present research found that in terms of hematological disorders, T-DM1 and T-DXd had a higher probability of reporting ADRs than TKIs. Moreover, the data showed that T-DM1 seemed to have a higher risk of cardiotoxicity than T-DXd, while T-DXd had a higher probability of reporting metabolism and nutrition disorders than T-DM1. Full article
(This article belongs to the Special Issue State-of-the-Art Drug Delivery in Europe)
►▼ Show Figures

Figure 1

14 pages, 2462 KiB  
Article
Cyclodipeptides: From Their Green Synthesis to Anti-Age Activity
by Veronica Mosetti, Beatrice Rosetti, Giovanni Pierri, Ottavia Bellotto, Simone Adorinni, Antonella Bandiera, Gianpiero Adami, Consiglia Tedesco, Matteo Crosera, Greta Camilla Magnano and Silvia Marchesan
Biomedicines 2022, 10(10), 2342; https://doi.org/10.3390/biomedicines10102342 - 20 Sep 2022
Cited by 5 | Viewed by 2436
Abstract
Cyclodipeptides (CDPs) or diketopiperazines (DKPs) are often found in nature and in foodstuff and beverages and have attracted great interest for their bioactivities, biocompatibility, and biodegradability. In the laboratory, they can be prepared by green procedures, such as microwave-assisted cyclization of linear dipeptides [...] Read more.
Cyclodipeptides (CDPs) or diketopiperazines (DKPs) are often found in nature and in foodstuff and beverages and have attracted great interest for their bioactivities, biocompatibility, and biodegradability. In the laboratory, they can be prepared by green procedures, such as microwave-assisted cyclization of linear dipeptides in water, as performed in this study. In particular, five CDPs were prepared and characterized by a variety of methods, including NMR and ESI-MS spectroscopies and single-crystal X-ray diffraction (XRD), and their cytocompatibility and anti-aging activity was tested in vitro, as well as their ability to penetrate the different layers of the skin. Although their mechanism of action remains to be elucidated, this proof-of-concept study lays the basis for their future use in anti-age cosmetic applications. Full article
(This article belongs to the Special Issue State-of-the-Art Drug Delivery in Europe)
►▼ Show Figures

Figure 1

14 pages, 3299 KiB  
Article
Novel Chloro-Substituted Salicylanilide Derivatives and Their β-Cyclodextrin Complexes: Synthesis, Characterization, and Antibacterial Activity
by Ioana Maria Carmen Ienașcu, Adina Căta, Mariana Nela Ştefănuț, Iuliana Popescu, Gerlinde Rusu, Paula Sfîrloagă, Daniel Ursu, Cristina Moşoarcă, Anamaria Dabici, Corina Danciu, Delia Muntean and Raluca Pop
Biomedicines 2022, 10(7), 1740; https://doi.org/10.3390/biomedicines10071740 - 19 Jul 2022
Cited by 4 | Viewed by 1864
Abstract
The goal of this research was to design novel chloro-substituted salicylanilide derivatives and their β-cyclodextrin complexes in order to obtain efficient antibacterial compounds and to demonstrate the beneficial role of complexation on the efficiency of these compounds. Thus, salicylanilide derivatives, esters, and hydrazides [...] Read more.
The goal of this research was to design novel chloro-substituted salicylanilide derivatives and their β-cyclodextrin complexes in order to obtain efficient antibacterial compounds and to demonstrate the beneficial role of complexation on the efficiency of these compounds. Thus, salicylanilide derivatives, esters, and hydrazides were obtained by microwave-assisted synthesis and their structure proven based on FTIR and NMR spectra. In order to improve water solubility, chemical and physical stability, and drug distribution through biological membranes, the inclusion complexes of the ethyl esters in β-cyclodextrin were also obtained using kneading. Inclusion-complex characterization was accomplished by modern analytical methods, X-ray diffraction, SEM, TGA, FTIR, and UV-vis spectroscopy. The newly synthesized compounds were tested against some Gram-positive and Gram-negative bacteria. Antimicrobial tests revealed good activity on Gram-positive bacteria and no inhibition against Gram-negative strains. The MIC and MBC values for compounds derived from N-(2-chlorophenyl)-2-hydroxybenzamide were 0.125–1.0 mg/mL. N-(4-chlorophenyl)-2-hydroxybenzamide derivatives were found to be less active. The inclusion complexes generally behaved similarly to the guest compounds, and antibacterial activity was not been altered by complexation. Full article
(This article belongs to the Special Issue State-of-the-Art Drug Delivery in Europe)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop